Spinouts always operate, by their very nature, on the cutting edge of science, but every once in a while, one comes along that could prove truly transformational by inventing an entirely new field.
Evox Therapeutics, which exploits research from University of Oxford and Karolinska Institute, is one of these: the spinout is a pioneer in the exosome therapeutics space – a new class of therapeutics that Evox is initially aiming at rare metabolic conditions but that has applications far beyond these target areas.
Evox, established in 2016, is building on work undertaken by Matthew Wood, professor of neuroscience and deputy head of the medical sciences division at Oxford, and Samir El…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
